You are on page 1of 3

Phi Life Sciences Launches Licensed Prostate Mitomic Test (PMT) for

Prostate Cancer Risk

Charleston, SC, December 19, 2016 --( Phi Life Sciences (Phi), a molecular diagnostic and
laboratory service company that empowers physicians to deliver precision treatments and diagnostics to
improve patient care and health, announced today that it has launched the Prostate Mitomic Test (PMT)
that is licensed from MDNA Life Sciences. Under the agreement, Phi is the first US partner to distribute
MDNA's proprietary liquid biopsy test that evaluates the risk of high-grade prostate cancer.
PMT is a liquid biopsy test for the prediction of high-grade prostate cancer in advance of biopsy. It is
intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have
high-grade cancer with a Gleason score of 7 or great that requires immediate intervention. As current
clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies, a follow-up
test such as PMT can significantly aid clinicians in differentiating between men who will benefit from
immediate biopsy from those who can avoid or delay such a costly and invasive procedure.
We chose Phi as our first commercial partner to offer PMT due to its strong network within the
molecular diagnostic space, said Chris Mitton, CEO of MDNA Life Sciences Inc. Launching PMT
with Phi will allow us to quickly build a user base to drive market acceptance and adoption. This valuable
partnership will also facilitate the collection of post-market data for PMT that will support of future
publications directed to clinical utility, which will be instrumental to our reimbursement efforts in the
broader US market, he added.
We are excited to offer MDNA's advanced liquid-biopsy test for prostate cancer. PMT is a valuable
addition to our test portfolio and aligns well with our vision to empower physicians to deliver more
precise clinical treatments and diagnoses. PMT is unique in the area of prostate cancer diagnostics
because it does not rely on the use of Prostate Specific Antigen detection, age, or race of a patient. It
provides our clinicians the ability to evaluate a patient's risk with a new molecular data point, said
Sawan Hurst, Chief Executive Officer of Phi Life Sciences.
About MDNA Life Sciences Inc.
MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests based on the
mitochondrial genome. The Company is applying its expertise in mitochondrial genomics to continue
development of an extensive and proprietary portfolio of blood-based molecular tests for conditions that
are currently dependent on poor or absent screening tests or invasive procedures for detection. For more
information visit
About Phi Life Sciences (Phi)
Phi is a commercialization catalyst for innovation and intends to become the leader in integrated
healthcare solutions by providing best-in-class clinical products supported by robust analytics. Phi's
mission is to revolutionize traditional medical practice through the application of a broad based suite of
Page 1/3 Press Release Distribution

Terms of Use

molecular diagnostic tests. For more information visit

Page 2/3 Press Release Distribution

Terms of Use

Contact Information:
Phi Life Sciences
Sawan Hurst
Contact via Email

Online Version of Press Release:

You can read the online version of this press release at:

News Image:

Page 3/3 Press Release Distribution

Terms of Use

You might also like